Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

AIMS: Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) are at very high risk of cardiovascular events. This post‐hoc analysis evaluated efficacy and safety of the PCSK9 inhibitor alirocumab among 984 individuals with DM and ASCVD pooled from 9 ODYSSEY P...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes Obes Metab
Egile Nagusiak: Ganda, Om P., Plutzky, Jorge, Sanganalmath, Santosh K., Bujas‐Bobanovic, Maja, Koren, Andrew, Mandel, Jonas, Letierce, Alexia, Leiter, Lawrence A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175384/
https://ncbi.nlm.nih.gov/pubmed/29802688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13384
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak